<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314766</url>
  </required_header>
  <id_info>
    <org_study_id>IC-8 203-LTCA</org_study_id>
    <nct_id>NCT03314766</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens</brief_title>
  <official_title>Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term clinical acceptability and overall
      satisfaction with the IC-8 IOL at least 12 months post-IOL implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, multi-center, non-interventional study in up to 80 patients
      previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol
      ACU-P14-029 at up to nine clinical sites within Europe.

      The purpose of this study is to demonstrate the long-term clinical acceptability and overall
      satisfaction in patients implanted with the IC-8 IOL. The primary study endpoint is binocular
      target-corrected near visual acuity (TCNVA) of 20/32 or better in 85% or more patients at
      least 12 months post-implantation. The secondary study endpoint is overall satisfaction with
      postoperative vision in 85% or more patients reporting either satisfied or very satisfied at
      least 12 months post-implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TCNVA</measure>
    <time_frame>12 months</time_frame>
    <description>Binocular target-corrected near visual acuity (TCNVA) of 20/32 or better in 85% or more patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Overall satisfaction with postoperative vision at least 12 months post-operatively, with an outcome of objective of 85% or more being either very satisfied or satisfied.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cataract</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>IC-8 IOL</arm_group_label>
    <description>Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IC-8 IOL</intervention_name>
    <description>Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation</description>
    <arm_group_label>IC-8 IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients for this study will be recruited from the clinical sites that participated in the
        prior open-label, multicenter study (protocol ACU-P14-029). Anticipated study sample size
        of no more than 80 patients should effectively demonstrate the long-term clinical
        acceptability of the IC-8 IOL implanted in aphakic patients.

        Patients will be screened for eligibility, and an informed consent will be obtained from
        those who meet the screening criteria and are interested in participating in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients previously implanted contralaterally or bilaterally with the IC-8 IOL under
             the protocol ACU-P14-029 and have had the IOL implanted for a duration of at least 12
             months and currently have the IC-8 IOL in the eye.

          2. Availability, willingness, ability and sufficient cognitive awareness to comply with
             examination procedures at the study visit.

          3. Signed informed consent.

        Exclusion Criteria:

        1. Patients who have developed systemic or ocular pathology, not related to the IOL that
        affected their best corrected distance visual acuity to be 0.8 decimal or worse as
        determined by diagnostic testing or investigator's medical judgment. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, OD</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Tarantino, OD</last_name>
    <phone>9495859511</phone>
    <email>ntarantino@acufocus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Srividhya Vilupuru, OD, PhD</last_name>
    <phone>9495859511</phone>
    <email>svilupuru@acufocus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augen Zentrum Nordwest</name>
      <address>
        <city>Ahaus</city>
        <zip>48683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Barte-Lohmann</last_name>
    </contact>
    <investigator>
      <last_name>Stefanie Schmickler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitats-Augenklinik, Department of Ophthalmology</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Buchner</last_name>
    </contact>
    <investigator>
      <last_name>Prof. H. Burkhard Dick, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Bassano Hospital</name>
      <address>
        <city>Bassano del Grappa</city>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franca Oro</last_name>
    </contact>
    <investigator>
      <last_name>Simonetta Morselli, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Toso, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Microchirurgia Ambulatoriale</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika De Lorenzo</last_name>
    </contact>
    <investigator>
      <last_name>Matteo Piovella, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ifocus Øyeklinikk</name>
      <address>
        <city>Haugesund</city>
        <zip>5527</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Østenstad</last_name>
    </contact>
    <investigator>
      <last_name>Kjell Gundersen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QVision (Unidad Oftalmología Hospital Virgen del Mar)</name>
      <address>
        <city>Almería</city>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Joaquín Fernández, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia, Servicio de Oftalmología</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Mendicute del Barrio</last_name>
    </contact>
    <investigator>
      <last_name>Javier Mendicute del Barrio, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

